Allarity Therapeutics, Inc. Share Price & Technical Analysis
ALLR · $1.65 (-6.78%)
Healthcare / Biotechnology
$1.65
-6.78%
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead dr…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
29% return in May, -39% avg return in past 3 year May month.
57% return in 2026, -264% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -9% | 0% | 10% | 27% | 29% | – | – | – | – | – | – | – | 57% |
| 25 | -8% | -27% | 13% | 20% | -25% | 11% | 0% | 50% | 7% | 0% | -7% | -15% | 17% |
| 24 | -22% | -13% | -26% | -80% | -51% | -64% | -15% | 2% | -60% | -33% | -21% | 9% | -374% |
| 23 | -14% | -25% | -75% | -74% | -41% | -39% | -60% | -24% | -55% | -26% | 1% | -3% | -434% |
| 22 | -26% | -50% | -51% | -28% | 87% | -53% | -8% | 4% | -7% | -47% | -22% | -28% | -228% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Strong · Uptrend
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer. It is also developing stenoparib with temozolomide, a PARP and WNT inhibitor in combination with a DNA-alkylating chemotherapy agent, which is in a Phase 2 clinical trial for patients with relapsed small cell lung cancer; and stenoparib-DRP, a companion diagnostic product used to select patients for stenoparib treatment. Allarity Therapeutics, Inc. is headquartered in Tarpon Springs, Florida.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$24.11M
P/E ratio
—
52W high
$2.35
52W low
$0.77
Volume
2,69,801
Beta
0.38
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Allarity Therapeutics, Inc. share price today?
- Allarity Therapeutics, Inc. (ALLR) last traded around $1.65 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ALLR have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ALLR. Download the app for real-time alerts.
- How can I analyze Allarity Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.